MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the
issuance of class a common...
$145,999K
Net cash provided by
(used in) financing...
$145,999K
Net increase
(decrease) in cash and cash...
$133,056K
Canceled cashflow
$12,943K
Share-based compensation
expense
$2,780K
Prepaid and other assets
-$281K
Depreciation and
amortization
$104K
Amortization of right-of-use
asset - operating
$99K
Net cash used in
operating activities
-$12,938K
Net cash used in
investing activities
-$5K
Canceled cashflow
$3,264K
Net loss
-$15,157K
Purchases of property and
equipment
$5K
Accounts payable,
accrued and other...
-$905K
Lease liabilities
-$140K
Back
Back
Cash Flow
source: myfinsight.com
OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. (OKUR)